Dr. Amanda Ricciuto completed her medical degree and Paediatrics training in Montreal at McGill University. She then completed fellowship training in Paediatric Gastroenterology at SickKids, including advanced training in the management of paediatric inflammatory bowel disease (IBD). During that time, she obtained her PhD in Clinical Epidemiology and Health Care Research at the Institute of Health Policy, Management and Evaluation at the University of Toronto. Ricciuto’s areas of specialty included paediatric inflammatory bowel disease and IBD-associated liver disease, particularly primary sclerosing cholangitis.
Ricciuto’s research is focused on paediatric inflammatory bowel disease (IBD) with a special interest in the intersection between IBD and a liver disease termed primary sclerosing cholangitis (PSC). PSC has no effective medical treatment and represents an important source of morbidity and mortality in IBD populations. She is a member of the Canadian Children IBD Network, a Canada-wide initiative aimed at optimizing treatment and better understanding causes of IBD in children. Two additional, currently ongoing projects include a cohort study aimed at identifying molecular predictors of treatment response in pediatric IBD, and a microbiome study aimed at identifying and characterizing microbes that are implicated in PSC/IBD disease processes.
Education and experience
- 2019–present: Physician, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, ON
- 2019–present: Assistant Professor, Department of Paediatrics, Faculty of Medicine, University of Toronto, Toronto, ON
- 2019–present: Associate Scientist, Child Health and Evaluative Sciences (CHES), SickKids Research Institute, The Hospital for Sick Children, Toronto, ON
- 2015–2019: PhD, Clinical Epidemiology and Health Care Research, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON
- 2006–2011: MDCM, Medicine, McGill University, Montreal, QC
- 2016: Dick Hamilton Award, Division of Gastroenterology, SickKids
- 2017: Child Health Evaluative Sciences (CHES) Exceptional Trainee Award, SickKids Research Institute
- 2017: Fellow Research Award, North American Society of Pediatric Gastroenterology Hepatology and Nutrition (NASPGHAN), Las Vegas, U.S.
- 2019: Beverly Antle Award, CHES, SickKids Research Institute
- 2019: Sass-Kortsak Award, SickKids Research Institute
- 2019: Claire Bombardier PhD Platinum Award, Institute of Health Policy, Management and Evaluation, University of Toronto
- 2019: Gerard Odell Award for Excellence in Liver Disease Research, NASPGHAN, Chicago, U.S.
- 2019: Young Faculty Clinical Investigator Award, NASPGHAN, Chicago, U.S.
- Ricciuto A, Hansen BE, Ngo B, Aloi M, Walters TD, Church PC, et al. Primary Sclerosing Cholangitis in Children With Inflammatory Bowel Diseases Is Associated With Milder Clinical Activity But More Frequent Subclinical Inflammation and Growth Impairment. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2020;18(7):1509-17.e7.
- Patil K*, Ricciuto A*, Alsharief A, Al-Rayahi J, Amirabadi A, Church PC, et al. Magnetic Resonance Cholangiopancreatography Severity Predicts Disease Outcomes in Pediatric Primary Sclerosing Cholangitis: A Reliability and Validity Study. Hepatology communications. 2020;4(2):208-18. * denotes equal contribution.
- Deneau MR, Mack C, Perito ER, Ricciuto A, Valentino PL, Amin M, Amir AZ, Aumar M, Auth M, Broderick A, DiGuglielmo M, Draijer LG, Tavares Fagundes ED, El-Matary W, Ferrari F, Furuya KN, Gupta N, Hochberg JT, Homan M, Horslen S, Iorio R, Jensen MK, Jonas MM, Kamath BM, Kerkar N, Kim KM, Kolho KL, Koot BG, Laborda TJ, Lee CK, Loomes KM, Martinez M, Miethke A, Miloh T, Mogul D, Mohammed S, Mohan P, Moroz S, Ovchinsky N, Palle S, Papadopoulou A, Rao G, Rodrigues Ferreira A, Sathya P, Schwarz KB, Shah U, Shteyer E, Singh R, Smolka V, Soufi N, Tanaka A, Varier R, Vitola B, Woynarowski M, Zerofsky M, Zizzo A, Guthery SL. The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) index: a prognostic tool for children. Hepatology (Baltimore, Md). 2020.
- Ricciuto A, Fish J, Carman N, Walters TD, Church PC, Hansen BE, et al. Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2018;16(7):1098-105.e1.
- Ricciuto A, Dhaliwal J, Walters TD, Griffiths AM, Church PC. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis. Journal of Crohn's & colitis. 2018;12(11):1302-15.
- 2020–2021: Principal Investigator. Serum Cytokine Profiles to Predict Anti-TNF Response in Pediatric Inflammatory Bowel Disease. Crohn’s and Colitis Foundation of America. PRO-KIIDS.
- 2020–2024: Co-Principal Investigator. Role of microbes in the pathogenesis of PIBD: From discovery, through causation, to novel treatments. CIHR.
- 2020–2023: Co-Applicant. Defining and Targeting Autoimmune Liver Disease. CIHR.
- 2020–2024: Co-Applicant. Defining the immune dysregulation underlying Pediatric IBD to better diagnose and treat patients. CIHR.
- 2019–2020: Principal Investigator. Serum Cytokine Profile for Predicting Anti-TNF Responsiveness in Pediatric IBD. Future Leaders in IBD (FLIBD).